Skip to main content
×
×
Home

Management of antipsychotic-induced hyperprolactinaemia

  • Sumeet Gupta, Dev A. M. Lakshmanan, Udayan Khastgir and Rajesh Nair
Summary

Hyperprolactinaemia is a common endocrine disorder that can be associated with significant morbidity. Antipsychotic medications are frequently linked to hyperprolactinaemia. This disorder usually presents as menstrual problems in women and sexual problems in men, which affect the patients' quality of life and adherence to antipsychotic treatment. In the past, treatment for hyperprolactinaemia was recommended only for symptomatic patients. However, it has become clear that persistent asymptomatic hyperprolactinaemia can be associated with long-term physical morbidities such as osteoporosis and possibly breast cancer. Hence, it is imperative that hyperprolactinaemia is managed even if asymptomatic when initially detected. This article discusses the various management options, such as reducing the dose of antipsychotic medication, switching to a prolactin-sparing antipsychotic and adding aripiprazole to the treatment regimen.

Learning Objectives

• Understand the physiology of the prolactin hormone

• Be able to judge when to intervene if a patient on an antipsychotic medication presents with hyperprolactinaemia

• Learn about the different treatment options

Copyright
Corresponding author
Correspondence Dr Sumeet Gupta, West Park Hospital, Edward Pease Way, Tees, Esk and Wear Valleys NHS Foundation Trust, Darlington DL2 2TS, UK. Email: sumeet.gupta@nhs.net
Footnotes
Hide All

For another view on this important topic, see Wadoo et al (2017) Hyperprolactinaemia: a guide for psychiatrists. BJPsych Advances, 23: 158–166.

Declaration of Interest

S.G. has received speaker fees from Lundbeck. U.K. has received an honorarium for chairing a meeting from Lundbeck. R.N. has received speaker fees from Lundbeck and Sunovion, and sponsorship for educational meetings from Lundbeck and Jansenn.

Footnotes
References
Hide All
Azoulay, L, Yin, H, Renoux, C (2011) The use of atypical antipsychotics and the risk of breast cancer. Breast Cancer Research and Treatment, 129: 541–8.
Bargiota, SI, Bonotis, KS, Messinis, IE, et al (2013) The effects of antipsychotics on prolactin levels and women's menstruation. Schizophrenia Research and Treatment, article ID 502697 (http://dx.doi.org/10.1155/2013/502697).
Barnes, TRE (2011) Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 25: 567620.
Ben-Jonathan, N, Hugo, ER, Brandebourg, TD, et al (2006) Focus on prolactin as a metabolic hormone. Trends in Endocrinology and Metabolism, 17: 110–6.
Bostwick, JR, Guthrie, SK, Ellingrod, VL (2009) Antipsychotic-induced hyperprolactinemia. Pharmacotherapy, 29: 6473.
Buckley, PF, Correll, CU (2008) Strategies for dosing and switching antipsychotics for optimal clinical management. Journal of Clinical Psychiatry, 69: 417.
Bushe, C, Shaw, M (2007) Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. Journal of Psychopharmacology, 21: 768–73.
Chen, CK, Huang, YS, Ree, SC, et al (2010) Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 34: 1495–9.
Citrome, L (2008) Current guidelines and their recommendations for prolactin monitoring in psychosis. Journal of Psychopharmacology, 22: 90–7.
Correll, CU, Detraux, J, De Lepeleire, J, et al (2015) Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry, 14: 119–36.
Crews, MP, Howes, OD (2012) Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. Human Psychopharmacology, 27: 1523.
De Berardis, D, Fornaro, M, Serroni, N, et al (2014) Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 8: 30–7.
De Hert, M, Correll, CU, Bobes, J, et al (2011) Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry, 10: 5277.
De Hert, M, Peuskens, J, Sabbe, T, et al (2016) Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatrica Scandinavica, 133: 522.
Ezzat, S, Asa, SL, Couldwell, WT, et al (2004) The prevalence of pituitary adenomas: a systematic review. Cancer, 101: 613–9.
Freeman, ME, Kanyicska, B, Lerant, A, et al (2000) Prolactin: structure, function, and regulation of secretion. Physiological Reviews, 80: 1523–631.
Froes Brandao, D, Strasser-Weippl, K, Goss, PE (2016) Prolactin and breast cancer: the need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients. A review. Cancer, 122: 184–8.
Harvey, PW, Everett, DJ, Springall, CJ (2008) Adverse effects of prolactin in rodents and humans: breast and prostate cancer. Journal of Psychopharmacology, 22: 20–7.
Holt, RI, Peveler, RC (2011) Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clinical Endocrinology, 74: 141–7.
Inder, WJ, Castle, D (2011) Antipsychotic-induced hyperprolactinaemia. Australian & New Zealand Journal of Psychiatry, 45: 830–7.
Ishioka, M, Yasui-Furukori, N, Sugawara, N, et al (2015) Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers. Neuropsychiatric Disease and Treatment, 11: 477–84.
Klibanski, A, Biller, BM, Rosenthal, DI et al (1999) Effects of prolactin and estrogen deficiency in amenorrheic bone loss. Journal of Clinical Endocrinology & Metabolism, 67: 124–30.
Landgraf, R, Landraf-Leurs, MM, Weissmann, A, et al (1977) Prolactin: a diabetogenic hormone. Diabetologia, 13: 99104.
Lee, BH, Han, CS, Kim, KH (2005) Treatment in risperidone-induced amenorrhoea. International Journal of Psychiatry in Clinical Practice, 9: 2934.
Li, X, Tang, Y, Wang, C (2013) Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS One, 8: e7017.
Lodhi, RJ, Masand, S, Malik, A (2016) Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study. Schizophrenia Research, 170: 245–51.
Madhusoodanan, S, Parida, S, Jimenez, C (2010) Hyperprolactinemia associated with psychotropics: a review. Human Psychopharmacology, 25: 281–97.
Melmed, S, Casanueva, FF, Hoffman, AR, et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 96: 273–88.
Milano, W, D'Acunto, CW, De Rosa, M, et al (2011) Recent clinical aspects of hyperprolactinemia induced by antipsychotics. Reviews on Recent Clinical Trials, 6: 5263.
National Institute for Health and Care Excellence (2014a) Psychosis and Schizophrenia in Adults: Prevention and Management (Clinical Guideline CG178). NICE.
National Institute for Health and Care Excellence (2014b) Bipolar Disorder: Assessment and Management (Clinical Guideline CG185). NICE.
O'Keane, V (2008) Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. Journal of Psychopharmacology, 22: 70–5.
Peuskens, J, Pani, L, Detraux, J, et al (2014) The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs, 28: 421–53.
Peveler, RC, Branford, D, Citrome, L, et al (2008) Antipsychotics and hyperprolactinaemia: clinical recommendations. Journal of Psychopharmacology, 22: 98103.
Rahman, T, Clevenger, CV, Kaklamani, V, et al (2014) Antipsychotic treatment in breast cancer patients. American Journal of Psychiatry, 171: 616–21.
Ranjbar, F, Sadeghi-Bazargani, H, Niari Khams, P, et al (2015) Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia. Neuropsychiatric Disease and Treatment, 11: 549–55.
Riecher-Rössler, A, Rybakowski, JK, Pflueger, MO (2013) Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychological Medicine, 43: 2571–82.
Serri, O, Chik, CL, Ur, E, et al (2003) Diagnosis and management of hyperprolactinemia. Canadian Medical Association Journal, 169: 575–81.
Shimatsu, A, Hattori, N (2012) Macroprolactinemia: diagnostic, clinical, and pathogenic significance. Clinical and Developmental Immunology, 4 Dec: doi 10.1155/2012/167132 [Epub].
Takeuchi, H, Remington, G (2013) A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology, 228: 175–85.
Torre, DL, Falorni, A (2007) Pharmacological causes of hyperprolactinemia. Therapeutics and Clinical Risk Management, 3: 929–51.
Tsuboi, T, Bies, RR, Suzuki, T, et al (2013) Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 45: 178–82.
Wang, AT, Mullan, RJ, Lane, MA, et al (2012) Treatment of hyperprolactinemia: a systematic review and meta-analysis. Systematic Reviews, 1: 33.
Wennbo, H, Gebre-Medhin, M, Gritli-Linde, A, et al (1997) Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. Journal of Clinical Investigation, 100: 2744–51.
Wong-Anuchit, C (2016) Clinical management of antipsychotic-induced hyperprolactinemia. Perspectives in Psychiatric Care, 52: 145–52.
Wu, H, Deng, L, Zhao, L, et al (2013) Osteoporosis associated with antipsychotic treatment in schizophrenia. International Journal of Endocrinology, 17 Apr: doi 10.1155/2013/167138 [Epub].
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Advances
  • ISSN: 2056-4678
  • EISSN: 2056-4686
  • URL: /core/journals/bjpsych-advances
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 2
Total number of PDF views: 134 *
Loading metrics...

Abstract views

Total abstract views: 302 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 22nd June 2018. This data will be updated every 24 hours.

Management of antipsychotic-induced hyperprolactinaemia

  • Sumeet Gupta, Dev A. M. Lakshmanan, Udayan Khastgir and Rajesh Nair
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *